For the past 15 years tamoxifen has been the standard adjuvant hormone therapy for women with early-stage breast cancer and estrogen receptor (ER)-positive tumors, irrespective of nodal status and other clinicopathological parameters. Recent studies provided evidence that the optimal duration of tamoxifen treatment is 5 years. Based on the positive clinical results obtained with the administration of aromatase inhibitors (AIs) in the metastatic setting, several controlled clinical trials have evaluated the efficacy and side effects of AIs versus standard tamoxifen also as adjuvant therapy in postmenopausal breast cancer patients. The results of the above studies, suggest a therapeutic advantage of AIs over tamoxifen with regard to relapse-free survival and the risk of metachronous contralateral breast cancer. We review the rationale and the available clinical data on initial or sequential hormone treatment with AIs and we propose a novel scenario for possible therapeutic strategies based on the clinicopathological characteristics of the patients and on the biology of each single tumor. (Int J Biol Markers 2006; 21: 111-22)
INTRODUCTION
Endocrine therapy is of substantial benefit in the majority of women with hormone-responsive breast cancer (BC). In the advanced setting, compelling evidence has demonstrated the value of aromatase inhibitors (AIs) in postmenopausal women (1) . Until recently, tamoxifen (tam) has been the standard adjuvant hormone therapy for early BC since its approval by the Food and Drug Administration in 1986 for node-positive (N+) disease and in 1990 for node-negative (N0) disease. Several prospective controlled randomized clinical trials have provided evidence for the usefulness of AIs in the adjuvant setting of postmenopausal hormone-responsive BC (2) . These studies include three strategies: (a) extended adjuvant therapy with AIs administered after ~5 years of tam, (b) a "switching" approach with AIs given after 2-3 years of tam to complete a maximum of 5 years of treatment, and (c) the up-front adjuvant therapy with AIs to replace tam. These strategies involve different populations of patients. The cohorts of patients entered in the extended adjuvant studies probably include a smaller proportion of patients with hormone-insensitive BC than the cohorts studied in the first-line setting. It is not clear which is the optimal hormone therapy for postmenopausal BC. Recent data suggest that in estrogen-receptor-positive (ER + ), proges-terone-receptor-positive (PR + ) patients, tam is much more effective than in ER + , PRpatients or patients with HER2 + tumors (3) . We do not know the biological mechanisms of the advantage of AIs in HER2 + and PR -BC; however, the known molecular mechanisms of tam resistance play a pivotal role in this subset of patients. Therefore, AIs seem to be the preferable endocrine therapy in patients with PRtumors and/or HER2 + tumors.
MECHANISMS OF RESISTANCE TO TAMOXIFEN
Resistance to endocrine therapy, either inherent or acquired during treatment, is a major challenge for disease management. The principal causes of hormone resistance include the following mechanisms: ER activation in the absence of estrogens; hypersensitivity of ER to low levels of circulating estrogens; and ER activation, rather than inhibition, by estrogen antagonists (4) . At the molecular level, several mechanisms have been described, including ER mutations resulting in increased sensitivity to ligand or coactivator (CoA) recruitment, with consequent enhanced ER activity; increased expression of the CoAs that mediate ER activity; downregulation of corepressor (CoR) activity with a reduced inhibitory effect of tam; and post-transcriptional modifications with ligand-indepen-dent activation of ER. The post-transcriptional modifications of ER are mainly triggered by activation of growth factor-signaling pathways. Because ER also has mitogenic and antiapoptotic effects through direct interaction with key components of several signal transduction pathways (nongenomic signaling), altered activity of these pathways may contribute to the resistance (4) .
Recent studies describe 4 pathways of ER activation (5) . ER binding to estrogen response elements (EREs) in target genes is regulated by coregulator complex (classical pathway) (5, 6) . ER can act without DNA binding by modulating gene expression at alternative regulatory sequences such as AP-1, SP-1, and USF sites (non-classical pathway) (5, 7) . Several other stimuli can activate the ER pathway in a ligand-independent manner (ligand-independent non-classical pathway) (5) . Finally, growth factors, such as insulin-like growth factor I (IGF-I), epidermal growth factor (EGF), heregulin and others, potentiate this alternative pathway (5) . One of the mechanisms of ER activation is phosphorylation of ER or its coregulators at specific sites induced by growth factors (8) . ER is phosphorylated at different sites by multiple kinases including the extracellular regulated kinase (ERK) 1/2 and p38 mitogen-activated protein kinases (MAPKs), cyclin-dependent kinase (CDK)-2, CDK-7, c-SRC, protein kinase A, pp90 rsk1 , and AKT (5) . Several signaling kinases, including ERK1/2, c-Jun NH2-terminal kinase (JNK), and p38 MAPK, phosphorylate members of the p160 SRC family of CoAs, and especially AIB1 (9) (10) (11) . Phosphorylation of CoAs augments their activity in ER-dependent transcription, even in the absence of ligands or in the presence of antiestrogens, by increasing their subcellular nuclear localization, their interaction with ER, and their ability to recruit other transcriptional coregulators to the receptorpromoter complex. In addition, phosphorylation may also directly activate intrinsic enzymatic activities of the CoAs such as acetyltransferase activity (9) (10) (11) . Like ER CoAs, CoR action is also regulated by multiple signal transduction pathways (12) .
ER directly interacts with and modulates several signaling pathways (membrane-initiated steroid signaling pathway), such as the IGF pathway (13) . Estrogen can increase the expression of IGF-I receptor (IGF-IR) and insulin receptor substrate-1 (IRS-1) and, conversely, IGFs phosphorylate and activate ER in a ligand-independent manner (14, 15) . Estrogen activates IGF-I signaling via ERK1/2 and also stimulates the link of ERα with the p85 subunit of phosphatidylinositol 3'-kinase (PI3K), resulting in subsequent PI3K activation (16, 17) . ERα interacts with IRS-1, and this complex translocates to the nucleus and binds to the pS2 promoter (18) . ER can also interact with shc (5) . Reduction of shc expression inhibits the formation of ER/IGF-IR complex, and reduction of IGF-IR inhibits the association of ER/shc (5) . In addition, membrane ERs can act as G-protein-coupled receptors. G-protein activation, via c-Src, leads to activation of matrix metalloproteinases, which, in turn, cleave and liberate heparin-binding EGF (HB-EGF). This free HB-EGF, acting in an autocrine manner, is responsible for the activation and phosphorylation of EGFR (19) . Overexpression of HER2/neu potentiates these interactions (20) . The functional interactions of ER and its coregulators with pathways activated by growth factor signaling are described in Figure 1 .
Recently, Wang et al (21) showed that p21-activated kinase 1 (Pak1) phosphorylates ER at Ser 305 and promotes its transactivation in ligand-independent phenotypes. Also Pak1 has been shown to upregulate cyclin D 1 expression in an ER-independent, but nuclear factor B-dependent, manner (22) . Functional dysregulation of specific Pak1 substrates (other than ER) has been implicated in Pak1-associated cancer phenotypes and hormone independence. Dynein light chain 1 (DLC1), a component of the dynein motor, is a physiological Pak1-interacting substrate and Pak1 phosphorylation of DLC1 at Ser 88 plays a critical role in supporting the anchorage-independent growth of BC cells in vitro and in nude mice (23) . DLC1 was dysregulated in most of the BC samples and approximately half the tumors had higher than normal expression of both Pak1 and DLC1 (23) . DLC1 interacts with ER and facilitates its transactivation functions through a novel coactivator (24) , modulating the sensitivity to estrogens. DLC1 overexpression increases the expression of the ER-regulated cell survival protein Bcl-2 and enhances the recruitment of DLC1-ER complex to ER target gene chromatin. Conversely, DLC1 downregulation significantly inhibits the ability of estrogens to induce PR and cathepsin D expression and reduces both the nuclear accumulation and the transactivation functions of ER, suggesting that DLC1 may have chaperone-like activity in the nuclear translocation of ER (24) . ER coregulatory proteins have been found in both nuclear and cytoplasmic cell compartments, raising the possibility that ER coregulators are involved in the nongenomic effects of estrogens and are subject to regulation by growth factor-initiated pathways. Such effects are exemplified by proline-, glutamic acid-, and leucine-rich protein 1/modulator of nongenomic activity of ER (PELP1/MNAR), which regulates both nuclear and extranuclear estradiol responses (25, 26) . Differential com-partmentalization of PELP1/MNAR may play a crucial role in modulating the status of nongenomic signaling using molecular mechanisms that remain poorly understood (27) . PELP1-cyto cells form early and aggressive tumors compared with those arising from wild-type PELP1 cells (which contain PELP1/MNAR in both the nucleus and the cytoplasm), and these tumors exhibit resistance to tamoxifen (28) . Further characterization of cytoplasmic PELP1/MNAR functions shows a possible interaction with a trafficking molecule that activates MAPK in the presence of EGFR by sequestering PELP1/MNAR in the cytoplasm. PELP1/MNAR is a unique CoA that modulates genomic and nongenomic actions of ER (28) . PELP1/MNAR recruitment to ER target gene chromatin and its interactions with histones, histone acetyltransferase enzymes, and deacetylase components suggest that PELP1/MNAR participates in chromatin remodeling activity. Deregulation of PELP1/MNAR localization may sequester ER in the cytoplasm or cell membrane. It is also possible that mislocalization of PELP1/MNAR may alter the ratio of genomic to nongenomic signaling in tumor cells, thus promoting hormonal independence by modulating ER-transactivating functions and selective ER-modulator actions. Growth factor signaling leading to modification of PELP1/MNAR could be another mechanism of hormonal resistance. These findings suggest that PELP1/MNAR expression or localization could be used to determine whether a tumor is hormone resistant or hormone susceptible (28, 29) .
The metastasis-associated genes (MTA) family of ER coregulators may also regulate these pathways (30) . MTA1 is a CoR of genomic ER activity by recruitment of histone deacetylases to ER transcriptional complexes (31) . A naturally occurring variant, MTA1s, not only downregulates nuclear ER activity but, by sequestering ER in the cytoplasm, simultaneously increases ER cytoplasmic or membrane signaling (30, 31) .
A number of studies have suggested a causal association between overexpression or aberrant activity of HER2 and antiestrogen resistance (8, 32) . HER2 overexpression is associated with enhanced metastatic behavior and poor prognosis (33) . Patients with HER2-overexpressing tumors exhibit lower response rates and/or shorter duration of response to tam therapy (34) . Overexpression of the EGFR and/or its ligands has also been associated with antiestrogen resistance (35) . Overexpression of HER2 in tam-sensitive MCF-7 BC cells results in MAPK hyperactivity and resistance to antiestrogens (20) . In addition, ER + BC cells grown in estrogen-depleted conditions exhibit increased MAPK activity (36) , which makes cells more sensitive to the mitogenic effects of low concentrations of estrogen (36) . MAPK promotes ER phosphorylation of Ser 118 and increases the association of ER with CoAs but decreases its association with CoRs, thus favoring hormone-induced gene transcription (12) . Administration of gefitinib, an oral EGFR tyrosine kinase inhibitor, for 4 to 6 weeks to patients with ER + /EGFR + BC has recently been shown to inhibit Ser 118 ERα phosphorylation and Tyr 845 EGFR phosphorylation (37) , suggesting that the activated EGFR cross-talks with ER signaling and potentially regulates its function in hormone-dependent BC. Activated ER enhances the transcription of EGFR ligands (38) , thus establishing a positive feedback loop that amplifies the output of the cross-talk between polypeptide growth factor and steroid receptors. Because both aberrant EGFR and HER2 hyperactivate MAPK, overexpression of these receptors enhances the agonistic effects of tam on ER-mediated transcription and leads to antiestrogen resistance.
The ligand-independent recruitment of CoA complexes to estrogen-responsive promoters, as the result of HER2 overexpression, may play a role also in the development of resistance to letrozole (39) .
Response to endocrine therapy correlates with hormone receptor status. Whereas ER is the accepted predictor of response to endocrine therapy, the role of PR is more controversial. Several trials, both in the adjuvant and advanced settings, found that patients with ER + /PR + tumors benefit much more from tam than patients with ER + /PRtumors (40) (41) (42) . ER + /PRtumors in postmenopausal women seem to be related to low circulating levels of estrogens, which are unable to stimulate ER to synthesize PR. Consistent with this hypothesis, ER + /PRtumors are more common in women of more than 50 years of age (43) . Some studies have shown that ER and PR status may change during the natural history of the disease (44) and treatment (45) . There are several mechanisms that explain the generation of ER + /PR -BCs, including nonfunctional ER (46), low circulating estrogen levels (47) , hypermethylation of PR promoter (48) , loss of het-erozygosity of the PR gene (49), growth factor downregulation of PR (50), selective ER modulator or growth factor-induced membrane ER activity (8) , or altered ER coregulator activity (51, 52) . The loss of PR may be due to multiple mechanisms, including hypermethylation of the PR promoter and loss of heterozygosity of the PR gene (53) . Several gowth factor signaling pathways directly downregulate PR levels via the PI3K/Akt/mTOR pathway, independently of ER (53) . Therefore, the absence of PR may not simply reflect a lack of ER activity but also a hyperactive cross-talk between ER and growth factor signaling pathways. Consistent with this hypothesis, several clinical studies have found that ER + /PR -BCs overexpress HER1 and HER2 (53) . Furthermore, loss of PTEN, a negative regulator of the PI3K/Akt signaling pathway, has been shown to be associated with specific loss of PR and no change in ER levels (53) .
ADJUVANT HORMONE THERAPY: GENERAL FIND-INGS
The definition of risk categories is the most important tool in the choice of the most effective adjuvant treatment. The 2005 St Gallen expert consensus Panel stated that for selection of adjuvant systemic therapy the first consideration is endrocine responsiveness; three categories have been acknowledged and they have been further divided according to the menopausal status and the Panel has classified the patients into risk categories (low, intermediate, and high) (Tab. I). Regarding postmenopausal woman appropriate hormone regimens include: an AI alone (anastrozole or letrozole) for 5 years or tam for 2-3 years followed by an AI (exemestane or anastrozole) to complete 5 years of therapy or the switch to an AI (letrozole) after 5 years of tam. Selected patients at low risk or with co-morbid muscolo-skeletal or cardiovascular risk factors may be considered suitable for tam alone. The American Society of Clinical Oncology (AS-CO) Technology Assessment on the use of AIs has approved the following statements: a) AIs are a reasonable alternative to tam for any postmenopausal woman with ER + tumor; b) AIs are the treatment of choice for women with contraindications to tam; c) after 5 years of tam, therapy with AIs should be considered for a minimum of 2.5 years, and d) the use of AIs is associated with increased osteoporosis, fracture risk, arthralgias and/or myalgias (54) .
TAMOXIFEN
As demonstrated by the randomized trials reviewed by the Oxford team (55), 5 years' tam treatment is superior to shorter treatments to prevent local and distant recurrences, new tumors in the contralateral breast, and the risk of death. The absolute improvement in 10-year survival is more than 10% for node-positive patients and 5% for node-negative patients. Women treated with 5 years of tam continue to benefit after cessation of therapy, with a lower risk of recurrence as compared to untreated women. However, even patients treated with tam present a stage-dependent residual risk of recurrence that persists over at least the following decade (1.5-2% yearly risk) (56) . The efficacy of tam is mainly related to the levels of ER expression, but PR expression is a further predictive marker. In fact, a retrospective analysis of data collected from 2 of the largest studies on adjuvant therapy in early BC, with ER and PR levels measured in 2 quality-controlled laboratories, showed that patients with ER + /PR + tumors benefited much more from adjuvant tam therapy than those with ER + /PRtumors. Moreover, multivariate analysis showed that both ER and PR were independent predictors of survival (40) . The predictive role of PR in the adjuvant tam setting has been confirmed by two other studies (57, 58) . During tam therapy PR levels decrease dramatically in up to 50% of tumors, and patients whose tumor cells lost PR have a poorer survival than those in whose tumor cells PR is retained (59) . Such ER + /PRtumors often overexpress also HER2 and EGFR, show a more aggressive behavior, and patients have a worse overall survival (OS). In one study, among tumors that recurred during tam treatment, about 10% of those that were initially HER2acquired HER2 overexpression. Therefore, also HER2 expression should be taken into account before planning any therapeutic clinical decisions. On the other hand, many patients with ER + /PR + tumors do not benefit from tam because of primary resistance or acquired resistance after an initial benefit; the hazard ra-tios of recurrence present a peak at the second year of follow-up and then decline. Again, tam is associated with a risk of thromboembolic disease and endometrial cancer, which increases during treatment. Thus, 5 years' standard adjuvant tam therapy is recommended to avoid the risk of enhanced long-term side effects.
AROMATASE INHIBITORS (AIs)
The pivotal study approaching the switch strategy was conducted by Boccardo and coworkers using the first generation of AIs. Patients receiving adjuvant tamoxifen treatment for 3 years were randomized to either continue tamoxifen for 2 more years or to switch to low-dose aminoglutethimide for 2 years. Switching patients resulted in comparable event-free survival, but longer overall survival (p=0.005) (60) . Seven trials have been conducted to verify the efficacy of 3 different third-generation AIs (anastrozole, letrozole, exemestane) in 3 different clinical settings: as monotherapy for 5 years in the upfront adjuvant setting; after 2-3 years of tam ("early switch"), or after 5 years of tam therapy for 5 years ("extended therapy" or "late switch") (Tab. II). The 3 different settings involve patients at different time points in the natural history of the disease with different hormone sensitivity because of selection made as a result of recurrences (1.5% to 3.8% per year of tam-treated patients develop treatment failure before cross-over), withdrawal for toxicity, and early death by any cause. Other confounding factors concern the tumor characteristics of the enrolled patients, and the different definitions of the end-points considered in the trials (disease-free survival [DFS], recurrence-free survival [RFS], event-free survival [EFS]). RFS is the most sensitive end-point for evaluating the efficacy of BC treatment because it includes distant and local recurrences as well as contralateral tumors. It is preferable to DFS, which also includes non-BC-related deaths in patients without a recurrence or second tumors (61) (62) (63) (64) . Distant DFS has an important value as surrogate endpoint for overall survival. Until mature results are available from trials directly comparing the up-front use of AI vs sequential use TAM-AI (ie, BIG 1-98), clinical decisions for women with hormone-sensitive early BC should still be based on the best available efficacy data for each treatment scenario, taking into account both the tolerability of each agent and the patient preference. Overall, based on published data, AIs are superior to tam in terms of efficacy in all patient subpopulations by reducing the risk of both distant metastasis and local recurrence; in particular in BIG 1-98 trial, letrozole has demonstrated to be superior to tamoxifen in node positive BC patients and in patients previous treated with chemotherapy and to reduce the risk of distant metastasis by 27% versus tam. In the MA-17 study, letrozole has demonstrated a significant survival advantage over placebo been in node-positive BC patients.
In the up-front setting, 2 major trials comparing tam with an AI have been published. The ATAC trial (Arimidex, Tamoxifen, Alone or in Combination), after a median follow-up of 68 months, showed for the first time that anastrozole, compared with tam, significantly improved DFS (hazard ratio [HR], 0.87; p=0.01), and time to recurrence (HR, 0.79; p=0.0005) and significantly reduced distant metastasis (HR, 0.86; p=0.04) and contralateral BC (42% reduction, p=0.01) (3, 65) without impairing quality of life (66) . Major toxicity differences were characterized by a significantly lower incidence of fractures and arthralgias in the tam arm whereas thromboembolic events, ischemic cerebrovascular events, endometrial cancer, hot flushes and vaginal bleeding were less frequent with anastrozole. The Breast International Group (BIG) 1-98, a randomized 4-arm phase III study, compared 5 years of therapy with tam or letrozole, 2 years of tam followed by 3 years of letrozole and vice versa (67) . The primary end-point was DFS defined as the time from randomization to any event (local and distant recurrence, contralateral BC, any second non-breast cancer, death of any cause). After a median follow-up of 25.8 months, adjuvant treatment with letrozole, as compared with tam, significantly reduced the cumulative incidence of BC relapse. This difference became evident one year after ran-domization with an absolute difference of 3.4% at 5 years. As compared with tam, letrozole significantly reduced the risk of a DFS event (HR, 0.81, p=0.03) especially the risk of distant recurrence (HR, 0.73; p=0.001). Prospectively planned subgroup analyses of DFS showed that letrozole reduced the risk of recurrence by 30% in patients who received chemotherapy and by 29% in patients whith involved axillary lymph nodes. The beneficial effect of letrozole on DFS was independent of ER and PR status. In the ATAC trial, on the other hand, the benefit of anastrozole was predominantly seen in patients who had not received adjuvant chemotherapy and in node-negative patients, and particularly in patients with ER + /PRtumors. As regards the hormone receptor aspect, it has been suggested that the overall benefit of anastrozole over tamoxifen in the ATAC trial is largely a result of the reduced efficacy of tam in patients with ER + /PRtumors (5); these patients should therefore derive greater benefit from initial therapy with an AI.
Three clinical trials have explored the efficacy of switching to an AI after 2 to 3 years of tam therapy (IES; ABCSG-8/German Arimidex Nolvadex [ARNO 95]; Italian Tamoxifen Anastrozole [ITA]).
In the Intergroup Exemestane Study (IES), the improvement of DFS achieved by switching from tam to exemestane is consistent with the hypothesis that BC fre- quently becomes resistant to tam within the first 5 years of treatment. After a median follow-up of 30.6 months, a 32% reduction in risk corresponding to an absolute benefit in DFS of 4.7% at 3 years after randomization has been observed. There has been no significant difference in survival reported to date. Exemestane seems to be equally effective in PR + and PRsubgroups, as well as in N+ and N0 subgroups, contrary to what was reported in the ATAC trial. Compared with tam, exemestane is associated with a higher incidence of arthralgia, myalgia, diarrhea, and myocardial infarction (0.9% vs 0.5%), but a lower incidence of thromboembolic disease, gynecological symptoms, and cramps (68) . A bone substudy showed a significant reduction in bone-mineral density in patients treated with exemestane than in the tam group after 1 year of therapy.
In the ABCSG trial 8 and German Arimidex Nolvadex (ARNO 95), postmenopausal women with hormone-sensitive disease who had completed 2 years of tam therapy (20 or 30 mg/day) were randomized to continue tam therapy versus a switch to anastrozole. The primary endpoint was EFS, with "event" being defined as local or distant metastasis, or contralateral BC, while death was excluded. At a median follow-up of 28 months with about 55% of patients completing the planned therapy, the combined analysis reported a 40% decrease in the risk for an event in the anastrozole group as compared to the tam group (p=0.0009), corresponding to an absolute benefit of 3.1% at 3 years. Also in this trial no difference in overall survival was observed, which was not expected at this stage since about 75% of patients were N0. Both treatments were well tolerated, with no significant differences in toxicities but more fractures (p=0.015) and fewer thromboses (p=0.034) in the anastrozole arm. However, the fracture rate in the anastrozole group was lower than that seen at a similar point in the anastrozole group of the ATAC trial. This finding could suggest a continued protective effect of tam on bone (69) .
The ITA trial enrolled only N+ patients with ER + tumors who had undergone 2 to 3 years of tam therapy. Switching to anastrozole resulted in an impressively better EFS (p=0.0002), local RFS (p=0.003), and distantmetastasis-free survival (p=0.06). However, the benefit reported may be related to the inclusion of only N+ patients and to the fact that about 70% of patients also received adjuvant chemotherapy. Overall, more adverse events were recorded in the anastrozole group than in the tam group (p=0.04), with lipid metabolism disorders (9.3% vs 4%) and gastrointestinal symptoms (7.9% vs 2.7%) among the more frequent events. Musculoskeletal disorders (8.4% vs 12%) but gynecological changes (including endometrial carcinoma) (1% vs 11.3%) were less frequent (70) .
It must be emphasized that switching trials do not include those patients that have not completed 2 to 3 years of tam due to relapse or withdrawal for toxicity and thus are effectively based on a preselected population. Therefore, the hazard ratios versus tam are likely to be more favorable than in up-front adjuvant therapy trials.
The largest trial in the extended setting is the MA-17 trial, conducted by the Breast Cancer Intergroup of North America and other cooperative groups (EORTC). After 4.5 to 6 years of tam therapy, postmenopausal hormonesensitive patients were randomized to either letrozole or placebo. The primary end-point was DFS (death without BC recurrence and contralateral BC were not considered an event). The use of letrozole was associated with a 42% reduction in the risk of events as compared with the placebo group. Significant improvements in DFS for both N0 and N+ patients were observed the improvement in OS was significant in N+ patients. A higher incidence of arthralgia, hot flushes and osteoporosis was reported in the letrozole group, but the rates of bone fractures and cardiovascular events were similar (71) . At this time, there is no evidence that more than 5 years' administration of an AI is of benefit. To resolve this question, a second randomization has been planned in the MA-17 trial where patients who took letrozole in years 6 to 10 will continue the same therapy versus placebo for 5 more years.
In the ABCSG-6a trial, the second study exploring the extended setting, patients after 5 years of tam alone or in combination with aminoglutethimide for the first 2 years were randomized to either observation or anastrozole for 3 years. The results showed significantly fewer recurrences in the anastrozole group.
Collectively, the studies suggest a reduction in the risk of recurrence, confirming the residual risk in women following 5 years of tam therapy, with a survival benefit in specific subgroups of patients (72) . In Table III the principal toxicities reported for each trial are summarized.
POSSIBLE TREATMENT STRATEGIES
The results from the trials in the three settings have raised important questions about the optimal adjuvant strategy for hormone receptor-positive, early-stage BC. The American Society of Clinical Oncology Committee panel on AIs concluded that optimal adjuvant treatment for postmenopausal women includes an AI either as initial therapy or after treatment with tam but has not taken a precise position on the preferred strategy and underlines how closely related agents with similar mechanisms of action may have different toxicity profiles (54) .
The comparative analysis of the controlled clinical trials with AIs suggest an overall superiority of AIs versus treatments based only on tam; however, some relevant differences should be taken into account:
The BIG 1-98 trial documented a significantly better DFS in favor of letrozole (HR 0.81; p=0.003) and a 5year difference in breast cancer events of -3.4% (p<0.001). Subgroup analysis suggested more benefit of letrozole therapy in patients who also received adjuvant chemotherapy (HR 0.70 vs 0.85); in patients with N+ disease (HR 0.71 vs 0.96) and with ER + /PR + tumors (HR 0.67) versus ER + /PRtumors (HR 0.88). Regarding HER2 status only a small difference in favor of ER + /HER2 + tumors was found (HR 0.68 vs 0.72). The ATAC trial comparing anastrozole versus tam also demonstrated the superiority of the AI, but subgroup analysis revealed some different results with respect to the BIG 1-98 study: patients with N0 disease obtained a greater benefit that N+ patients; patients who did not receive adjuvant chemotherapy had more benefit, and patients with ER + /PRtumors had the highest absolute benefit of anastrozole (HR 0.43). There are no convincing explanations for the different findings between these two studies, particularly regarding the predictive value of PR, probably related in part to the lack of standardization of the assay method. The results of the MA-17 trial of sequential hormone therapy after 5 years of tam (letrozole versus placebo) suggest a significant benefit obtained with letrozole in terms of DFS for both N0 and N+ patients and of distant DFS in the subgroup of N+ patients only. The efficacy benefits of extended adjuvant letrozole were restricted to ER + /PR + patients and were absent in ER + /PRpatients (HR 0.49 vs 1.21; p=0.02). Finally, the ABCSG-6a trial found that at a median follow-up of 60 months, the risk of recurrence was significantly reduced (HR 0.64; p=0.047) in the arm receiving tam ± aminoglutethimide followed by anastrozole therapy.
Regarding the choice of adjuvant hormone therapy in postmenopausal women we suggest that the following variables should be taken into account for a tailored therapeutic approach (Fig. 2) :
Patients characterized by N0 disease, small tumors (pT1), well-differentiated tumors (G1), low proliferation index and ER expression in >50% of tumor cells or >50 fmol/mg and PR + are those who are likely to obtain the highest benefit of standard 5-year tam therapy. Patients with N+ disease, pT2-3 tumors, high/intermediate grade of differentiation (G2-3), low or moderate proliferation index, and ER + tumors are those who are more likely to obtain the highest benefit of sequential therapy with Ais.
Patients with ER + , PRand/or HER2 + tumors with a moderate/high proliferation index, irrespective of other characteristics, should be treated with first-line AI therapy.
Patients with a history of thromboembolic events, ischemic cerebrovascular events and endometrial hyperplasia are eligible for first-line IA therapy instead of tam.
Patients with a history of clinically relevant osteoporosis and arthralgia are eligible for tam alone.
The administration of adjuvant chemotherapy may also affect the choice of the subsequent hormone therapy, which is also related to the evidence that in certain trials (ATAC, BIG 1-98, ABCSG-8/ARNO 95) only a small proportion of the enrolled women received both adjuvant chemotherapy and hormone therapy. It is therefore not possible at this time to establish the possible cumulative/additive side effects in the patients enrolled in the above trials regarding treatment based on AIs and chemotherapy. Finally, no data are available on the possible efficacy of combined therapy with AIs and trastuzumab in the subset of patients with ER + and HER2 + tumors as initial or sequential therapy after chemotherapy.
CONCLUSIONS AND OPEN QUESTIONS
All the available data on the comparison between tam and AIs in postmenopausal women agree about the significant benefit in terms of DFS or RFS and reduced risk of contralateral breast cancer in favor of the latter therapy. The open questions concern the following points: 1) Which is the AI of choice for initial or sequential therapy after tam? Two controlled clinical trials are comparing the efficacy and tolerability of different AIs as first-line therapy. The MA-27 study evaluates adjuvant anastrozole versus exemestane and is ultimating the enrolment of the 6836 required patients. The FACE trial compares letrozole versus anastrozole in patients stratified for the number of metastatic axillary nodes and HER2 status. To achieve the estimated 80% 5-year DFS rate for letrozole versus 76.5% 5-year DFS for anastrozole a total of 4000 N+ patients will have to be randomized to achieve statistically significant power. 2) What is the optimal duration of therapy with AIs? 3) Which is the most efficacious and safe AI after adjuvant chemotherapy? 4) In patients with ER + and HER2 + tumors, should trastuzumab be administered in combination with AIs? 5) Taking into account the higher risk of osteoporosis in patients treated with AIs, should such a therapy be supported by preventive diphosphonates?
Further controlled clinical studies are needed to properly validate the results obtained with adjuvant AIs in terms of overall survival and long-term tolerability as well as to answer the above and other relevant clinical questions.
